Danaher Revenue & Financials

Danaher's ten-year financial trajectory illustrates an extraordinary transition from a diversified industrial enterprise into a high-margin life sciences and diagnostics pure-play. Consolidated revenues grew from $14.43 billion in FY2015 to a record peak of $26.64 billion in FY2022, fueled by explosive pandemic testing demand at Cepheid and urgent global bioprocessing demand for COVID-19 vaccine production at Cytiva. Following the successful spin-off of Veralto Corporation in September 2023 (which transferred ~$5.0 billion in environmental and product identification sales) and customer bioprocessing destocking, FY2024 revenue stabilized at $23.88 billion ($23,875 million), virtually unchanged from $23.89 billion in FY2023. Profitability and cash generation remain standout hallmarks of the franchise. In FY2024, Danaher generated $4.86 billion in operating profit and $4.20 billion in net income, resulting in a robust 17.59% net margin (approximately 17.6%). Operating cash flow reached $6.35 billion, with free cash flow conversion comfortably exceeding 125% of net income. Danaher closed FY2024 with $49.54 billion in stockholders' equity and a conservative net leverage ratio of approximately 1.5x EBITDA, giving management substantial balance sheet capacity to pursue bolt-on and programmatic acquisitions as biotech market valuations normalize.